<DOC>
	<DOC>NCT01527695</DOC>
	<brief_summary>This is a multi-centre study to be conducted in Sweden and Finland. Up to 24 male and/or female patients of non-childbearing potential aged 45 to 75 years (inclusive), with a clinical diagnosis Parkinson's Disease will be randomised in the study to allow for 20 patients to complete this study.The study will evaluate the effect of 8 weeks treatment with AZD3241 on microglia activation as measured via PET examinations.</brief_summary>
	<brief_title>PET Study in Parkinson's Disease Patients</brief_title>
	<detailed_description>A Phase IIA, Multi centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment with Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients with Parkinson's Disease</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Female and male patients aged 45 to 75 years (inclusive) at the day of enrolment (Visit 1) Female patients must have a negative pregnancy test at Screening, must not be lactating and must be of non childbearing potential, confirmed at Screening Male patients should be willing to use barrier contraception, eg, condoms, even if their partners are postmenopausal, be surgically sterile or are using accepted contraceptive methods, from the administration of the first dose of the investigational The clinical diagnosis of patients must meet the criteria for "diagnosis of idiopathic Parkinson's disease" according to the modified UKPDS Brain Bank criteria (see Appendix E) Modified Hoehn and Yahr stage 1 to 2 Diagnosis is unclear or a suspicion of other Parkinsonian syndromes exists, such as secondary Parkinsonism (caused by drugs, toxins, infectious agents, vascular disease, trauma, brain neoplasm), Parkinsonplus syndromes or heredodegenerative diseases Patients who have undergone surgery for the treatment of Parkinson's disease (eg, pallidotomy, deep brain stimulation, foetal tissue transplantation) or have undergone any other brain surgery Presence of significant dyskinesias, motor fluctuations, swallowing difficulties or loss of postural reflexes Patients with a history of nonresponse (according to both the clinician and the patient) to an adequate course of Ldopa or a DA agonist Use of pergolide, selegiline, metoclopramide, strong CYP3A4 inhibitors, CYP3A4 inducers (including St John's Wort) and strong CYP1A2 inhibitors and inducers, within 1 month of randomisation;</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Phase IIa</keyword>
	<keyword>AZD3241</keyword>
	<keyword>microglia activation</keyword>
	<keyword>safety</keyword>
	<keyword>Pharmacodynamics and pharmacokinetics analyses</keyword>
	<keyword>Parkinson patients</keyword>
</DOC>